- OHT-7’s Q1 2021 Report Card on EUA Reviews April 14, 2021
- HP&M’s Sara Koblitz to Present on Integrating FDA Regulatory Law into an IP Law Practice April 13, 2021
- AMPed up—again– over Medicaid Rebate False Claims Act allegations April 13, 2021
- Controlled Substances Act Issues: Legal Perspectives and Analytical Trends Webinar April 12, 2021
- Shhh! It’s a Secret! FDA is Not Providing Key Details in the EUA Templates April 12, 2021
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
FDA Law Blog Turns 3!
March 5, 2010Yep, it’s been three years since we started FDA Law Blog. And that means it’s time again to take a minute from blogging on FDA issues to pat ourselves on the back. It’s been a banner year for us. We recently topped 800 posts (almost 350 this past year alone) , started a Twitter page, and our readership continues to grow – we are nearing 4,000 subscribers. That’s a lot for a niche blog! And, while we like any “major prize,” we are particularly proud that the American Bar Association named FDA Law Blog as one of the top legal “blawgs” in the blogosphere when the organization announced the ABA Blawg 100 last December. We’re hoping for a repeat this year.
Thank you again to our loyal readers! We appreciate your thoughtful comments, even though we do not always post them. We also thank our Hyman, Phelps & McNamara, P.C. colleagues for their time and dedication to writing interesting and informative posts.
So here’s to three great years . . . . and hopefully many more to come!
Search FDA Law Blog
Subscribe
Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- The Best
Lawyers in America
US News & World Report - Ranked in Chambers USA 2018
- OHT-7’s Q1 2021 Report Card on EUA Reviews April 14, 2021
- HP&M’s Sara Koblitz to Present on Integrating FDA Regulatory Law into an IP Law Practice April 13, 2021
- AMPed up—again– over Medicaid Rebate False Claims Act allegations April 13, 2021
- Controlled Substances Act Issues: Legal Perspectives and Analytical Trends Webinar April 12, 2021
- Shhh! It’s a Secret! FDA is Not Providing Key Details in the EUA Templates April 12, 2021
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized